Trial Profile
Double blind, placebo controlled randomised trial assessing the efficacy of endothelin-1 receptor antagonism against placebo in the prevention of microvascular injury in patients with non-ST elevation acute coronary syndrome (NSTEACS) undergoing percutaneous coronary intervention: the ENDORA-PCI trial
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 24 Jun 2016
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Acute coronary syndromes
- Focus Pharmacodynamics
- Acronyms ENDORA-PCI
- 14 Aug 2015 New trial record